Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Harvard University · Brigham and Women's Hospital · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
591
total citations
- FWCI
- 76.54
- Percentile
- 100%
- References
- 31
Citations per year
Authors
16- MSMarc S. SabatineCorresponding
Harvard University, Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group
- LALawrence A. Leiter
University of Toronto, St. Michael's Hospital
- SDStephen D. Wiviott
Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group
- RPRobert P. Giugliano
Harvard University, Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group
- PDPrakash Deedwania
California State University, Fresno
Topics & keywords
Topics
Keywords
- Medicine
- Evolocumab
- PCSK9
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
- Clinical endpoint
- Myocardial infarction
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.